Hepion Pharmaceuticals (Hepion Pharmaceuticals) 6-Month Price Index : 0.29 (As of May. 01, 2024)

View and export this data going back to 2014. Start your Free Trial

What is Hepion Pharmaceuticals 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-05-01), Hepion Pharmaceuticals's 6-Month Price Index is 0.29.

Competitive Comparison of Hepion Pharmaceuticals's 6-Month Price Index

For the Biotechnology subindustry, Hepion Pharmaceuticals's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Hepion Pharmaceuticals (NAS:HEPA) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index

Current Share Price

Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Hepion Pharmaceuticals (NAS:HEPA) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.

Hepion Pharmaceuticals 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Hepion Pharmaceuticals's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.

Hepion Pharmaceuticals (Hepion Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Hepion Pharmaceuticals Inc (NAS:HEPA) » Definitions » 6-Month Price Index

Comparable Companies

Traded in Other Exchanges

N/A

Address

399 Thornall Street, First Floor, Edison, NJ, USA, 08837

Website

https://www.hepionpharma.com

Hepion Pharmaceuticals Inc is a biopharmaceutical company that focuses primarily on the development of drug therapy for the treatment of chronic liver diseases. This therapeutic approach targets fibrosis and hepatocellular carcinoma associated with non-alcoholic steatohepatitis, viral hepatitis, and other liver diseases. Its cyclophilin inhibitor, Rencofilstat, is being developed to offer benefits to address these multiple complex pathologies. Rencofilstat is a pan cyclophilin inhibitor that targets multiple pathologic pathways involved in the progression of liver disease.

Executives

Peter Wijngaard	director	8 SYLVAN WAY, PARSIPPANY NJ 07054
Robert T Foster	officer: Chief Scientific Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Kaouthar Lbiati	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
Anand Reddi	director	399 THORNALL STREET, FIRST FLOOR, EDISON NJ 08837
John T Cavan	officer: Chief Financial Officer	C/O STEMLINE THERAPEUTICS, INC., 750 LEXINGTON AVENUE, 6TH FLOOR, NEW YORK NY 10022
John P Brancaccio	director	C/O TAMIR BIOTECHNOLOGY, INC., 11 DEER PARK DRIVE, SUITE 204, MONMOUTH JUNCTION NJ 08852
Gary S Jacob	director, officer: CEO and President
Donald E Garlikov	10 percent owner	41 S. HIGH STREET, SUITE 3400, COLUMBUS OH 43215
Tamar D Howson	director
Thomas Phd Adams	director
Gabriel Cerrone	10 percent owner	VIA SANT' ANDREA 18, MILAN L6 20121
John Z Sullivan-bolyai	officer: Chief Medical Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 399 THORNALL STREET, 1ST FLOOR, EDISON NJ 08837
James Sapirstein	director, officer: Chief Executive Officer	1517 SAN JACINTO, HOUSTON TX 77002
Arnold Lippa	director	C/O AURORA CAPITAL, LLC, 17 PARK AVENUE, #201, NEW YORK NY 10016
William Karl Hornung	officer: Chief Financial Officer	C/O CONTRAVIR PHARMACEUTICALS, INC., 420 LEXINGTON AVE., SUITE 300, NEW YORK NY 10170